MedPath

Off-label use of Risperidone in Children and Adolescents (ORCA): a double-blind placebo-controlled discontinuation trial

Recruiting
Conditions
Risperidone, long-term efficacy and safety, risperidon, langetermijn effectiviteit
Registration Number
NL-OMON20175
Lead Sponsor
niversity Medical Center Groningen (UMCG)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Be between the ages of six and seventeen years and eight months

Exclusion Criteria

- Risperidone was discontinued for ≥ two months in the last year.

- Current psychosis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure will be the D-total score of the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath